{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:51:53Z","timestamp":1753890713031,"version":"3.41.2"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T00:00:00Z","timestamp":1627603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background and Aims<\/jats:title><jats:p>Several clinical trials have proved the efficacy of clopidogrel treatment for patients with percutaneous coronary intervention. There are few large-scale studies to identify the mortality associated with different durations of treatment of clopidogrel in patients with diabetes and ACS undergoing PCI in the Chinese population. The objective of this analysis was to determine the efficacy of long-term clopidogrel therapy (\u226512 months) <jats:italic>versus<\/jats:italic> short-term use (&amp;lt;12 months) in Chinese patients with diabetes after PCI.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and Results<\/jats:title><jats:p>We used the Beijing Municipal Medical Insurance Database provided by the Beijing Municipal Medical Insurance Bureau. The Beijing Municipal Medical Insurance Database contained medical data of about 16 million people, including about 990,000 patients with diabetes and a history of taking antidiabetic medicines. Patients were divided into two groups, one group of 9,116 patients receiving consecutive clopidogrel for one year or more, and another group of 3290 patients receiving consecutive clopidogrel for less than one year. The primary outcomes of this analysis were the risk of all-cause death, myocardial infarction, and revascularization. In patients with diabetes after PCI, long-term clopidogrel treatment was associated with a reduced risk of all-cause death (HR, 0.57[95%CI, 0.49-0.67], P&amp;lt;0.0001), myocardial infarction (HR, 0.79[95%CI, 0.68-0.93], P=0.0035) and an increased risk of angina (HR, 1.18[95%CI, 1.10-1.27], P&amp;lt;0.0001]) and revascularization (HR, 1.07[95%CI, 1.01-1.13], P=0.02]). There was no significant difference in the prevalence of all-cause re-hospitalization, diabetes-related re-hospitalization, and cerebrovascular re-hospitalization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The present study concluded that long-term dual antiplatelet therapy including clopidogrel and aspirin could decrease the risks of all-cause death, myocardial infarction. But it could increase the risks of angina and revascularization. Further studies should interpret the cause of this question.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.713849","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T08:38:58Z","timestamp":1627634338000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database"],"prefix":"10.3389","volume":"12","author":[{"given":"Weihao","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuli","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4","article-title":"Effects of Pretreatment With Clopidogrel and Aspirin Followed by Long-Term Therapy in Patients Undergoing Percutaneous Coronary Intervention\u00a0: The PCI-CURE Study","volume":"358","author":"Mehta","year":"2001","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2411","article-title":"Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention-A Randomized Controlled Trial","volume":"288","author":"Berger","year":"2002","journal-title":"JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation The Task Force for the Management of Acute Myocardial Infarction","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E1596","DOI":"10.1016\/S0735-1097(13)61596-X","article-title":"Non-Adherence With Clopidogrel After Coronary Stenting Is Associated With Increased Mortality and Myocardial Infarction","volume":"61","author":"Din","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/2012.jama.10779","article-title":"Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction","volume":"308","author":"Andersson","year":"2012","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","first-page":"A124","DOI":"10.1016\/S0735-1097(14)60124-8","article-title":"The High Event Rate in Patients With Diabetes Mellitus Treated With PCI for Acute Coronary Syndromes Is Observed in the Subgroup of Patients With Impaired Renal Function: Results of the Alkk-PCI Registry","volume":"63","author":"Zeymer","year":"2014","journal-title":"J Am Coll Cardiol"},{"volume-title":"Idf Diabetes Atlas","year":"2017","author":"Huang","key":"B7"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7596","article-title":"Prevalence and Ethnic Pattern of Diabetes and Prediabetes in China in 2013","volume":"317","author":"Wang","year":"2017","journal-title":"JAMA"},{"key":"B9","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s12933-018-0793-x","article-title":"Prevalence and in \u2212 Hospital Outcomes of Diabetes Among Patients With Acute Coronary Syndrome in China: Findings From the Improving Care for Cardiovascular Disease in China \u2212 Acute Coronary Syndrome Project","volume":"17","author":"Zhou","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2015.06.1339","article-title":"Long-Term Outcomes in Patients With Diabetes Mellitus Related to Prolonging Clopidogrel More Than 12 Months After Coronary Stenting","volume":"66","author":"Thukkani","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/eurheartj\/ehv443","article-title":"Long-Term Dual Antiplatelet Therapy for Secondary Prevention of Cardiovascular Events in the Subgroup of Patients With Previous Myocardial Infarction: A Collaborative Meta-Analysis of Randomized Trials","author":"Udell","year":"2015","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00286-1","article-title":"The Influence of Diabetes Mellitus on Acute and Late Clinical Outcomes Following Coronary Stent Implantation","volume":"32","author":"Abizaid","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-4145(07)70160-0","article-title":"Incidence, Predictors, and Outcome of Thrombosis After Successful Implantation of Drug-Eluting Stents","volume":"293","author":"Gersh","year":"2005","journal-title":"JAMA"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-Eluting Stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu318","article-title":"Endeavour Zotarolimus-Eluting Stent Reduces Stent Thrombosis and Improves Clinical Outcomes Compared With Cypher Sirolimus-Eluting Stent: 4-Year Results of the PROTECT Randomized Trial","volume":"35","author":"Wijns","year":"2014","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2012.04.004","article-title":"Adverse Cardiovascular Effects of Concomitant Use of Proton Pump Inhibitors and Clopidogrel in Patients With Coronary Artery Disease: A Systematic Review and Meta-Analysis","volume":"43","author":"Huang","year":"2012","journal-title":"Arch Med Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12872-016-0453-6","article-title":"Is the Concomitant Use of Clopidogrel and Proton Pump Inhibitors Still Associated With Increased Adverse Cardiovascular Outcomes Following Coronary Angioplasty?: A Systematic Review and Meta-Analysis of","volume":"17","author":"Bundhun","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2010.08.004","article-title":"Inhibition of the Antithrombotic Effects of Clopidogrel by Proton Pump Inhibitors: Facts or Fancies","volume":"21","author":"Lettino","year":"2010","journal-title":"Eur J Intern Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.110.958884","article-title":"Clinical Outcomes in Patients With the Concomitant Use of Clopidogrel and Proton Pump Inhibitors After Percutaneous Coronary Intervention: An Analysis From the Guthrie Health Off-Label Stent (GHOST) Investigators","volume":"4","author":"Harjai","year":"2011","journal-title":"Circ Cardiovasc Interv"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.07.058","article-title":"Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2y12 Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes","volume":"50","author":"Storey","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.912550","article-title":"Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET\/OFFSET Study","volume":"120","author":"Gurbel","year":"2009","journal-title":"Circulation"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehu160","article-title":"Ticagrelor vs. Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome With or Without Revascularization: Results From the PLATO Trial","volume":"35","author":"Lindholm","year":"2014","journal-title":"Eur Heart J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"20235","DOI":"10.7326\/0003-4819-155-4-201108160-02008","article-title":"Meta-Analysis: High-Dose Statin Pretreatment Prevents Periprocedural Cardiac Events in Patients Having PCI","volume":"155","author":"Patti","year":"2011","journal-title":"Ann Intern Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"237264","DOI":"10.1155\/2016\/8237264","article-title":"Fenofibrate Plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model","volume":"2016","author":"Oidor-chan","year":"2016","journal-title":"PPAR Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.713849\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T08:39:15Z","timestamp":1627634355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.713849\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,30]]},"references-count":25,"alternative-id":["10.3389\/fendo.2021.713849"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.713849","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2021,7,30]]},"article-number":"713849"}}